Physician profile
Eleanor Dewitt
NPI 1912993098
$3,572.34
in general payments reported to CMS, 2019-2025
27 companies · $26.99 in 2025
The $26.99 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,182 · 2020: $566 · 2021: $480 · 2023: $59.71 · 2024: $258 · 2025: $26.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $454.30 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $339.16 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $334.70 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.39 | 2019-2024 | Synjardy, Jardiance |
| Amgen INC. | $284.82 | 2019-2023 | Repatha, Otezla |
| Astellas Pharma US INC | $251.92 | 2019-2021 | |
| Lilly USA, LLC | $238.65 | 2019-2021 | |
| Glaxosmithkline, LLC. | $191.88 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $154.51 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $140.14 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $112.25 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.97 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $85.67 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $81.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $75.98 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $58.42 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.32 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $49.10 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $38.86 | 2021 | |
| Exact Sciences Corporation | $38.39 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $37.21 | 2019 | |
| Paratek Pharmaceuticals, INC. | $30.63 | 2021-2024 | Nuzyra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.21 | 2024 | Caplyta |
| Valeritas, INC. | $18.73 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.68 | 2024 | Rexulti |
| Genentech USA, INC. | $13.58 | 2019 | |
| Eisai INC. | $13.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleanor Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.